Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

PHASE3CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

August 31, 2018

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib

administration of Sorafenib

PROCEDURE

Hepatic arterial infusion chemotherapy

administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

DRUG

Folfox Protocol

Oxaliplatin , fluorouracil, and leucovorin

Trial Locations (5)

421001

First Affiliated Hospital of University Of South China, Hengyang

510060

Cancer Center Sun Yat-sen University, Guangzhou

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

510620

Guangzhou Twelfth People 's Hospita, Guangzhou

529300

The Kaiping Center's Hospital, Kaiping

All Listed Sponsors
collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Kaiping Central Hospital

OTHER

collaborator

Guangzhou No.12 People's Hospital

OTHER_GOV

collaborator

The First Affiliated Hospital of University of South China

OTHER

lead

Sun Yat-sen University

OTHER

NCT02774187 - Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | Biotech Hunter | Biotech Hunter